Physician Investigator (Cl) Cancer Center, Mass General Research Institute

Professor of Medicine Harvard Medical School

Associate Physician Medicine-Hematology/Oncology, Massachusetts General Hospital

MD Johns Hopkins University School of Medicine 1997

antineoplastic agents; benzenesulfonates; cancer clinical trials; carcinoma renal cell; melanoma; protein kinase inhibitors; proto-oncogene proteins b-raf; pyridines; skin neoplasms Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer. In this context he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.